Alzheimer’s Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time

Publisher： Karger

E-ISSN： 1664-5464|2|1|468-480

ISSN： 1664-5464

Source： Dementia and Geriatric Cognitive Disorders Extra, Vol.2, Iss.1, 2012-11, pp. : 468-480

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

By  

Dementia and Geriatric Cognitive Disorders, Vol. 35, Iss. 1-2, 2013-01 ,pp. : 23-33

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite

Impact of Gender Differences on the Outcome of Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 30, Iss. 2, 2010-08 ,pp. : 147-154

Karger

Access to resources Recommend Favorite

Two-Year Treatment of Alzheimer’s Disease with Eptastigmine

By  

Dementia and Geriatric Cognitive Disorders, Vol. 10, Iss. 2, 1999-02 ,pp. : 139-147

Karger

Access to resources Recommend Favorite